Cited by 195Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeural and Behavioral Psychology Studies

Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial

Open access
Williams, Leanne M, Korgaonkar, Mayuresh S, Song, Yun C, Paton, Rebecca, Eagles, Sarah, Goldstein-Piekarski, Andrea, Grieve, Stuart M, Harris, Anthony W F +2 more·2015·Neuropsychopharmacology

Abstract

Although the cost of poor treatment outcomes of depression is staggering, we do not yet have clinically useful methods for selecting the most effective antidepressant for each depressed person. Emotional brain activation is altered in major depressive disorder (MDD) and implicated in treatment response. Identifying which aspects of emotional brain activation are predictive of general and specific responses to antidepressants may help clinicians and patients when making treatment decisions. We examined whether amygdala activation probed by emotion stimuli is a general or differential predictor of response to three commonly prescribed antidepressants, using functional magnetic resonance imaging (fMRI). A test-retest design was used to assess patients with MDD in an academic setting as part of the International Study to Predict Optimized Treatment in Depression. A total of 80 MDD outpatients were scanned prior to treatment and 8 weeks after randomization to the selective serotonin reuptake inhibitors escitalopram and sertraline and the serotonin-norepinephrine reuptake inhibitor, venlafaxine-extended release (XR). A total of 34 matched controls were scanned at the same timepoints. We quantified the blood oxygen level-dependent signal of the amygdala during subliminal and supraliminal viewing of facial expressions of emotion. Response to treatment was defined by ⩾50% symptom improvement on the 17-item Hamilton Depression Rating Scale. Pre-treatment amygdala hypo-reactivity to subliminal happy and threat was a general predictor of treatment response, regardless of medication type (Cohen's d effect size 0.63 to 0.77; classification accuracy, 75%). Responders showed hypo-reactivity compared to controls at baseline, and an increase toward 'normalization' post-treatment. Pre-treatment amygdala reactivity to subliminal sadness was a differential moderator of non-response to venlafaxine-XR (Cohen's d effect size 1.5; classification accuracy, 81%). Non-responders to venlafaxine-XR showed pre-treatment hyper-reactivity, which progressed to hypo-reactivity rather than normalization post-treatment, and hypo-reactivity post-treatment was abnormal compared to controls. Impaired amygdala activation has not previously been highlighted in the general vs differential prediction of antidepressant outcomes. Amygdala hypo-reactivity to emotions signaling reward and threat predicts the general capacity to respond to antidepressants. Amygdala hyper-reactivity to sad emotion is involved in a specific non-response to a serotonin-norepinephrine reuptake inhibitor. The findings suggest amygdala probes may help inform the personal selection of antidepressant treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2015.89

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Normalization of emotional processing at behavioural and neural levels takes place during antidepressant treatment and correlates with clinical improvement.

    “normalization of emotional processing at behavioural and neural levels was shown to take place during AD treatment and to correlate with clinical improvement”
  • In a study comparing the SSRIs escitalopram and sertraline and the dual 5-HT and NA reuptake inhibitor venlafaxine-XR, amygdala hyporeactivity to happy and fearful faces at baseline predicted clinical responses across treatments, but amygdala hyperreactivity to sad faces specifically predicted a nonresponse to venlafaxine-XR.

    “In a study comparing the SSRIs escitalopram and sertraline and the dual 5-HT and NA reuptake inhibitor venlafaxine-XR, amygdala hyporeactivity to happy and fearful faces at baseline predicted clinical responses across treatments, but amygdala hyperreactivity to sad faces specifically predicted a nonresponse to venlafaxine-XR.82”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Williams, L. M., Korgaonkar, M. S., Song, Y. C., Paton, R., Eagles, S., Goldstein-Piekarski, A., Grieve, S. M., Harris, A. W. F., Usherwood, T., & Etkin, A.
Affiliations
  • The University of Sydney (AU)
  • VA Palo Alto Health Care System (US)
Corresponding author
Williams, Leanne M
Venue
Neuropsychopharmacology
Published
2015-03-31
Volume
40
Issue
10
Pages
2398-2408
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2026088841
Cited by
195
References
52
Citations by year
2026: 6 · 2025: 16 · 2024: 22 · 2023: 10 · 2022: 10 · 2021: 42 · 2020: 16 · 2019: 17 · 2018: 21 · 2017: 18 · 2016: 14 · 2015: 3
FWCI
13.45
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
Keywords
amygdala reactivity, major depressive disorder, antidepressant response, treatment response prediction, emotional face processing, venlafaxine extended release, sertraline, escitalopram, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors
MeSH terms
Venlafaxine Hydrochloride, Adult, Amygdala, Antidepressive Agents, Major Depressive Disorder, Emotions, Facial Expression, Female, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Oxygen, Photic Stimulation, Predictive Value of Tests, Psychiatric Status Rating Scales, Citalopram, Case-Control Studies, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review